Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03982368 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate Safety and Efficacy of rhNGF Eye Solution vs Vehicle in Patients With Moderate to Severe Dry Eye
A Phase 2 study, sponsored by Dompé Farmaceutici S.p.A.
- Completed
- Registry status
- Phase 2
- Development phase
- 261
- Enrollment target
NCT03982368 is a Phase 2 study that has completed, run by Dompé Farmaceutici S.p.A. The registered enrollment target is 261 participants.
The verdict
NCT03982368, a Phase 2 study, has completed, sponsored by Dompé Farmaceutici S.p.A.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 261 participants
- Enrollment target
Study Summary
The objective of this study is to assess the efficacy and safety of rhNGF eye drops at 20 μg/ml concentration administered two or three times daily for 4 weeks in patients with moderate to severe dry eye.
Interventions
- OTHER Vehicle
- DRUG rhNGF 20 μg/ml
- DRUG rhNGF 20 μg/ml + vehicle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 261 participants |
| Start Date | 2019-06-10 |
| Est. Completion | 2020-07-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03982368
The ClinicalTrials.gov registry entry for NCT03982368 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 261 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dompé Farmaceutici S.p.A, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Vehicle is the first listed.
NCT03982368 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03982368 about?
NCT03982368 is a clinical study titled "A Study to Evaluate Safety and Efficacy of rhNGF Eye Solution vs Vehicle in Patients With Moderate to Severe Dry Eye". The objective of this study is to assess the efficacy and safety of rhNGF eye drops at 20 μg/ml concentration administered two or three times daily for 4 weeks in patients with moderate to severe dry eye.
What is the current status of trial NCT03982368?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 261 participants. The study started on 2019-06-10. Estimated completion is 2020-07-15.
What interventions are being tested in trial NCT03982368?
The interventions under investigation include: Vehicle (OTHER), rhNGF 20 μg/ml (DRUG), rhNGF 20 μg/ml + vehicle (DRUG).
Who is sponsoring clinical trial NCT03982368?
This trial is sponsored by Dompé Farmaceutici S.p.A, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.